Pulmonary hypertension: the value of experimental medicine in new drug development

PVRI Member Authors: Martin Wilkins


Pulmonary hypertension has enjoyed a great deal of interest from the pharmaceutical industry in recent years. Unfortunately, this is now waning, because the challenge of addressing the disease is perceived to be large, and the size of the market is perceived to be small. For new drugs, there is still the attraction of asking a premium price after licensing. But with a high attrition rate, the risks of bringing a new chemical entity to the market are still great.1 So how can academia help?

Published in:

Pulmonary Circulation Vol 4: No 2 cover image

May 2014

Pulmonary Circulation Vol 4: No 2

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI